Ascendiant Capital Maintains Buy on Atossa Therapeutics, Raises Price Target to $6.5
Portfolio Pulse from Benzinga Newsdesk
Ascendiant Capital has maintained a Buy rating on Atossa Therapeutics and raised the price target from $6.25 to $6.5, indicating confidence in the company's future performance.
September 11, 2024 | 9:46 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ascendiant Capital has reaffirmed its Buy rating on Atossa Therapeutics and increased the price target to $6.5, suggesting a positive outlook for the company's stock.
The increase in the price target from $6.25 to $6.5 by Ascendiant Capital indicates a positive sentiment towards Atossa Therapeutics' future performance. This is likely to boost investor confidence and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100